Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Ketoconazole and LGD-4033 Interaction: Monitor | Peptide Database

Compound Profiles Ketoconazole Antifungal | Topical Anti-Androgen for Hair Loss Ketoconazole works through multiple pathways relevant to hair loss. As an azole antifungal, it inhibits the enzyme lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Ketoconazole

Antifungal | Topical Anti-Androgen for Hair Loss

Ketoconazole works through multiple pathways relevant to hair loss. As an azole antifungal, it inhibits the enzyme lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis and killing Malassezia fungi that colonize the scalp and contribute to inflammation and seborrheic dermatitis.

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Ketoconazole with LGD-4033?

Yes, but with caution. Both Ketoconazole and LGD-4033 carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects. Regular monitoring is advised.

Is Ketoconazole and LGD-4033 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic. Monitor accordingly.

What are the interactions between Ketoconazole and LGD-4033?

Both Ketoconazole and LGD-4033 carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time Ketoconazole and LGD-4033?

Ketoconazole has a half-life of Topical application stays local with minimal systemic absorption and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Prostamax — share findings, ask questions, and learn from real experiences Prostamax is a Khavinson bioregulator tetrapeptide (KEDP) with primary repair effects on prostate tissue. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it alters chromatin structure in cells from elderly individuals, promoting deheterochromatinization and potentially reactivating genes repressed during aging. Research in rat models shows reduced prostate inflammation, decreased swelling, and decelerated pathological remodeling associated with prostatitis. Prostamax works through epigenetic regulation by altering chromatin structure. It increases the frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs), while reducing large segments of pericentromeric heterochromatin. These changes promote chromatin decondensation and deheterochromatinization, potentially reactivating genes repressed during aging. The peptide influences heterochromatin arrangements in human lymphocytes and normalizes age-related changes in cellular function.

Source: peptide-db.com ↗

Community Research

Join others researching Chonluten — share findings, ask questions, and learn from real experiences Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD. Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Berberine is administered exclusively by the oral route, typically as berberine hydrochloride (HCl) capsules or tablets. Oral bioavailability is notably low (approximately 5%), which is a significant pharmacokinetic limitation. However, much of berberine's activity occurs locally in the gut and liver (first-pass metabolism), where concentrations are high regardless of systemic bioavailability. Dihydroberberine (DHB) is an alternative form that reportedly achieves higher plasma levels. Berberine should always be taken with meals to reduce gastrointestinal side effects and improve absorption. The short half-life (~4 hours) necessitates multiple daily doses to maintain therapeutic levels. General Metabolic Support / Blood Glucose Management 500 mg, 2-3 times daily 2-3x daily with meals Oral with meals Lipid Optimization MK-677 / GH Glucose Management 500 mg, 1-2 times daily 1-2x daily with meals Dihydroberberine (DHB) Alternative 100-200 mg, 2-3 times daily

Source: peptide-db.com ↗
Side effects

Common Side Effects

Fatigue and reduced exercise tolerance, particularly during the first week of use Cold extremities (hands and feet) due to beta-2 blockade of peripheral vasodilation Bradycardia (heart rate below 60 bpm), usually dose-dependent and asymptomatic Dizziness or lightheadedness, especially when standing quickly Gastrointestinal discomfort (nausea, diarrhea, constipation)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →